<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<base href="SCM%2012/12/24%201R">
<title>S3098 1R</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:AlbertusExtraBold;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.fronterpagebillhead
	{mso-style-name:fronterpagebillhead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FPHangingAnAct, li.FPHangingAnAct, div.FPHangingAnAct
	{mso-style-name:FPHangingAnAct;
	mso-style-link:"FPHangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.4in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.FPHangingAnActChar
	{mso-style-name:"FPHangingAnAct Char";
	mso-style-link:FPHangingAnAct;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;
	background:navy;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-weight:bold;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	letter-spacing:.2pt;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	letter-spacing:.2pt;
	font-weight:bold;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.0in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 1.3in 2.0in;}
div.WordSection3
	{page:WordSection3;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuReprint><a name=bpuFrontPg></a>[First Reprint]</p>

<p class=bpuBill>SENATE, No. 3098 </p>

<p class=bpuWpGraphic><b><span style='font-size:32.0pt;line-height:120%;
font-family:"Arial",sans-serif;letter-spacing:0pt'>STATE OF NEW JERSEY</span></b></p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>INTRODUCED APRIL 11, 2024</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:11.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Senator  VIN GOPAL</p>

<p class=bpuSponsor>District 11 (Monmouth)</p>

<p class=bpuSponsor>Senator  TROY SINGLETON</p>

<p class=bpuSponsor>District 7 (Burlington)</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>Co-Sponsored by:</p>

<p class=bpuSponsor>Senators A.M.Bucco, Johnson, Greenstein, Pennacchio,
Diegnan, McKnight, Beach, Cruz-Perez, Zwicker, Bramnick, Burgess, Singer and
Wimberly</p>

<p class=MsoNormal>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Requires health insurers to provide coverage for
biomarker testing. </p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     As reported by the Senate Commerce Committee on
December 12, 2024, with amendments.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif;
letter-spacing:.2pt'><br clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:150%'><b><span
style='line-height:150%;font-variant:small-caps'>An Act</span></b> concerning
health insurance coverage for biomarker testing <b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span style='font-family:
"Albertus Extra Bold",sans-serif'>[</span></b>and amending<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>1</sup></span></b>
and supplementing various parts of the statutory law.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      1.   a. 
Each hospital service corporation contract that provides hospital or medical
expense benefits and is delivered, issued, executed, or renewed in this State
pursuant to P.L.1938, c.366 (C.17:48-1 et seq.) or is approved for issuance or
renewal in this State by the Commissioner of Banking and Insurance, on or after
the effective date of P.L.    , c.     (C.        ) (pending before the
Legislature as this bill), shall provide coverage for biomarker testing, as
defined by subsection g. of this section.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      b.   Biomarker
testing shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition of a subscriber
when the test is supported by medical and scientific evidence, including, but
not limited to:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1)  labeled
indications for an FDA-approved or FDA-cleared test; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  indicated
tests for an FDA-approved drug; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (3)  warnings
and precautions on FDA-approved drug labels;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (4)  Centers
for Medicare and Medicaid Services National Coverage Determinations or Medicare
Administrative Contractor Local Coverage Determinations; or</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (5)  nationally-recognized
clinical practice guidelines and consensus statements.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      c.   Coverage,
pursuant to subsection b. of this section, shall be provided in a manner that
limits disruption, including multiple biopsies or biospecimen samples, in the
care of a subscriber.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      d.   (1)        </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Notwithstanding any other law, rule, or regulation
to the contrary, if</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>If</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> utilization review is required, </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><u><span
style='letter-spacing:0pt'>a hospital service corporation shall provide</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> a decision </span><b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>shall be rendered on a prior authorization request,
and notice shall be sent to the subscriber and the appropriate health care
provider, and if the request is made through a health care entity, to the
health care entity, within 72 hours for a non-urgent request or 24 hours for an
urgent request</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>pursuant
to the guidelines and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et
al.)</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>1</span></sup></b><span style='letter-spacing:0pt'>.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  The
subscriber and the treating health care provider or treating health care entity
prescribing biomarker testing for the subscriber shall have access to clear,
readily accessible, and conspicuous information on the process to submit an
appeal to an adverse determination.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      e.   The
benefits shall be provided to the same extent as for any other medical
condition under the contract.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      f.    The
provisions of this section shall apply to all hospital service corporation
contracts in which the hospital service corporation has reserved the right to
change the premium.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      g.   As
used in this section:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
means a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a specific therapeutic intervention, including known
gene-drug interactions for medications being considered for use or already
being administered. Biomarkers shall also include, but not be limited to, gene
mutations, characteristics of genes, or protein expression.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker testing includes but is not limited to,
single-analyte tests, multiplex panel tests, protein expression, and whole
exome, whole genome, and whole transcriptome sequencing.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Consensus statement means a statement developed by
an independent, multidisciplinary panel of experts utilizing a transparent
methodology and reporting structure and with a conflict of interest policy. 
The statement shall be aimed at specific clinical circumstances and be based on
the best available evidence for the purpose of optimizing the outcomes of
clinical care.</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.</span><span style='font-size:11.5pt;line-height:150%;
letter-spacing:0pt'>  </span><span style='letter-spacing:0pt'>The guidelines
establish standards of care informed by a systematic review of evidence and an
assessment of the benefits and risks of alternative care options and include
recommendations intended to optimize patient care.</span><span
style='font-size:11.5pt;line-height:150%;letter-spacing:0pt'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      2.   a. 
Each medical service corporation contract that provides hospital or medical
expense benefits and is delivered, issued, executed, or renewed in this State
pursuant to P.L.1940, c.74 (C.17:48A-1 et seq.) or is approved for issuance or
renewal in this State by the Commissioner of Banking and Insurance, on or after
the effective date of P.L. &nbsp;&nbsp;&nbsp;, c.     (C.        ) (pending
before the Legislature as this bill), shall provide coverage for biomarker
testing, as defined by subsection g. of this section.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      b.   Biomarker
testing shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition of a subscriber
when the test is supported by medical and scientific evidence, including, but
not limited to:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1)  labeled
indications for an FDA-approved or -cleared test; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  indicated
tests for an FDA-approved drug; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (3)  warnings
and precautions on FDA-approved drug labels;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (4)  Centers
for Medicare and Medicaid Services National Coverage Determinations or Medicare
Administrative Contractor Local Coverage Determinations; or</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (5)  nationally-recognized
clinical practice guidelines and consensus statements.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      c.   Coverage,
pursuant to subsection b. of this section, shall be provided in a manner that
limits disruption, including multiple biopsies or biospecimen samples, in the
care of a subscriber.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      d.   (1)        </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Notwithstanding any other law, rule, or regulation
to the contrary, if</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>If</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> utilization review is required, </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><u><span
style='letter-spacing:0pt'>a medical service corporation shall provide</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> a decision </span><b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>shall be rendered on a prior authorization request,
and notice shall be sent to the subscriber and the appropriate health care
provider, and if the request is made through a health care entity, to the
health care entity, within 72 hours for a non-urgent request or 24 hours for an
urgent request</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>pursuant
to the guidelines and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1
et. al)</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>1</span></sup></b><span style='letter-spacing:0pt'>.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  The
subscriber and the treating health care provider or treating health care entity
prescribing biomarker testing for the subscriber shall have access to clear,
readily accessible, and conspicuous information on the process to submit an
appeal to an adverse determination.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      e.   The
benefits shall be provided to the same extent as for any other medical
condition under the contract.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      f.    The
provisions of this section shall apply to all medical service corporation
contracts in which the medical service corporation has reserved the right to
change the premium.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      g.   As
used in this section:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
means a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a specific therapeutic intervention, including known
gene-drug interactions for medications being considered for use or already
being administered. Biomarkers shall also include, but not be limited to, gene
mutations, characteristics of genes, or protein expression.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker testing includes but is not limited to,
single-analyte tests, multiplex panel tests, protein expression, and whole
exome, whole genome, and whole transcriptome sequencing.</span></p>

<p class=MsoNormal style='line-height:150%'><b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>        1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Consensus statement means a statement developed by
an independent, multidisciplinary panel of experts utilizing a transparent
methodology and reporting structure and with a conflict of interest policy.  The
statement shall be aimed at specific clinical circumstances and be based on the
best available evidence for the purpose of optimizing the outcomes of clinical
care.</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      3.   a. 
Each health service corporation contract that provides hospital or medical
expense benefits and is delivered, issued, executed, or renewed in this State
pursuant to P.L.1985, c.236 (C.17:48E-1 et seq.) or is approved for issuance or
renewal in this State by the Commissioner of Banking and Insurance, on or after
the effective date of P.L. &nbsp;&nbsp;&nbsp;, c.&nbsp; &nbsp; (C.        )
(pending before the Legislature as this bill), shall provide coverage for
biomarker testing, as defined by subsection g. of this section.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      b.   Biomarker
testing shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition of a subscriber
when the test is supported by medical and scientific evidence, including, but
not limited to:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1)  labeled
indications for an FDA-approved or -cleared test; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  indicated
tests for an FDA-approved drug; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (3)  warnings
and precautions on FDA-approved drug labels;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (4)  Centers
for Medicare and Medicaid Services National Coverage Determinations or Medicare
Administrative Contractor Local Coverage Determinations; or</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (5)  nationally-recognized
clinical practice guidelines and consensus statements.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      c.   Coverage,
pursuant to subsection b. of this section, shall be provided in a manner that
limits disruption, including multiple biopsies or biospecimen samples, in the
care of a subscriber.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      d.   (1)        </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Notwithstanding any other law, rule, or regulation
to the contrary, if</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>If</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> utilization review is required, </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><u><span
style='letter-spacing:0pt'>a health service corporation shall provide</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> a decision </span><b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>shall be rendered on a prior authorization request,
and notice shall be sent to the subscriber and the appropriate health care
provider, and if the request is made through a health care entity, to the
health care entity, within 72 hours for a non-urgent request or 24 hours for an
urgent request</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>pursuant
to the guidelines and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et
al.)</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>1</span></sup></b><span style='letter-spacing:0pt'>.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  The
subscriber and the treating health care provider or treating health care entity
prescribing biomarker testing for the subscriber shall have access to clear,
readily accessible, and conspicuous information on the process to submit an
appeal to an adverse determination.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      e.   The
benefits shall be provided to the same extent as for any other medical
condition under the contract.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      f.    The
provisions of this section shall apply to all health service corporation
contracts in which the health service corporation has reserved the right to
change the premium.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      g.   As
used in this section:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
means a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a specific therapeutic intervention, including known
gene-drug interactions for medications being considered for use or already
being administered. Biomarkers shall also include, but not be limited to, gene
mutations, characteristics of genes, or protein expression.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker testing includes but is not limited to,
single-analyte tests, multiplex panel tests, protein expression, and whole
exome, whole genome, and whole transcriptome sequencing.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Consensus statement means a statement developed by
an independent, multidisciplinary panel of experts utilizing a transparent
methodology and reporting structure and with a conflict of interest policy. 
The statement shall be aimed at specific clinical circumstances and be based on
the best available evidence for the purpose of optimizing the outcomes of
clinical care.</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      4.   a. 
Each individual health insurance policy that provides hospital or medical
expense benefits and is delivered, issued, executed, or renewed in this State
pursuant to chapter 26 of Title 17B of the New Jersey Statutes or is approved
for issuance or renewal in this State by the Commissioner of Banking and
Insurance, on or after the effective date of P.L. &nbsp;&nbsp;&nbsp;, c.&nbsp;
&nbsp; (C.        ) (pending before the Legislature as this bill), shall
provide coverage for biomarker testing, as defined by subsection g. of this
section.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      b.   Biomarker
testing shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition of an insured when
the test is supported by medical and scientific evidence, including, but not
limited to:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1)  labeled
indications for an FDA-approved or -cleared test; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  indicated
tests for an FDA-approved drug; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (3)  warnings
and precautions on FDA-approved drug labels;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (4)  Centers
for Medicare and Medicaid Services National Coverage Determinations or Medicare
Administrative Contractor Local Coverage Determinations; or</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (5)  nationally-recognized
clinical practice guidelines and consensus statements.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      c.   Coverage,
pursuant to subsection b. of this section, shall be provided in a manner that
limits disruption, including multiple biopsies or biospecimen samples, in the
care of an insured.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      d.   (1)        </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Notwithstanding any other law, rule, or regulation
to the contrary, if</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>If</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> utilization review is required, </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><u><span
style='letter-spacing:0pt'>a carrier shall provide</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> a decision </span><b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>shall be rendered on a prior authorization request,
and notice shall be sent to the insured and the appropriate health care
provider, and if the request is made through a health care entity, to the
health care entity, within 72 hours for a non-urgent request or 24 hours for an
urgent request</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>pursuant
to the guidelines and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et
al.)</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>1</span></sup></b><span style='letter-spacing:0pt'>.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  The
insured and the treating health care provider or treating health care entity
prescribing biomarker testing for the insured shall have access to clear,
readily accessible, and conspicuous information on the process to submit an
appeal to an adverse determination.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      e.   The
benefits shall be provided to the same extent as for any other medical
condition under the contract.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      f.    The
provisions of this section shall apply to all health benefits plans in which
the carrier has reserved the right to change the premium.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      g.   As
used in this section:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
means a characteristic that is objectively measured and evaluated as an indicator
of normal biological processes, pathogenic processes, or pharmacologic
responses to a specific therapeutic intervention, including known gene-drug
interactions for medications being considered for use or already being
administered. Biomarkers shall also include, but not be limited to, gene
mutations, characteristics of genes, or protein expression.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker testing includes but is not limited to,
single-analyte tests, multiplex panel tests, protein expression, and whole
exome, whole genome, and whole transcriptome sequencing.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Consensus statement means a statement developed by
an independent, multidisciplinary panel of experts utilizing a transparent
methodology and reporting structure and with a conflict of interest policy. 
The statement shall be aimed at specific clinical circumstances and be based on
the best available evidence for the purpose of optimizing the outcomes of
clinical care.</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      5.   a.
&nbsp;Each group health insurance policy that provides hospital or medical
expense benefits and is delivered, issued, executed, or renewed in this State
pursuant to chapter 27 of Title 17B of the New Jersey Statutes or is approved
for issuance or renewal in this State by the Commissioner of Banking and
Insurance, on or after the effective date of P.L. &nbsp;&nbsp;&nbsp;, c.&nbsp;
&nbsp; (C.        ) (pending before the Legislature as this bill), shall
provide benefits for biomarker testing, as defined by subsection g. of this
section.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      b.   Biomarker
testing shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition of an insured when
the test is supported by medical and scientific evidence, including, but not
limited to:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1)  labeled
indications for an FDA-approved or -cleared test; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  indicated
tests for an FDA-approved drug; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (3)  warnings
and precautions on FDA-approved drug labels;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (4)  Centers
for Medicare and Medicaid Services National Coverage Determinations or Medicare
Administrative Contractor Local Coverage Determinations; or</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (5)  nationally-recognized
clinical practice guidelines and consensus statements.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      c.   Coverage,
pursuant to subsection b. of this section, shall be provided in a manner that
limits disruption, including multiple biopsies or biospecimen samples, in the
care of an insured.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      d.   (1)        </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Notwithstanding any other law, rule, or regulation
to the contrary, if</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>If</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> utilization review is required, </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><u><span
style='letter-spacing:0pt'>an insurer shall provide</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> a decision </span><b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>shall be rendered on a prior authorization request,
and notice shall be sent to the insured and the appropriate health care
provider, and if the request is made through a health care entity, to the
health care entity, within 72 hours for a non-urgent request or 24 hours for an
urgent request</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>pursuant
to the guidelines and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et
al.)</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>1</span></sup></b><span style='letter-spacing:0pt'>.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  The
insured and the treating health care provider or treating health care entity
prescribing biomarker testing for the insured shall have access to clear,
readily accessible, and conspicuous information on the process to submit an
appeal to an adverse determination.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      e.   The
benefits shall be provided to the same extent as for any other medical
condition under the contract.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      f.    The
provisions of this section shall apply to all policies in which the insurer has
reserved the right to change the premium.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      g.   As
used in this section:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
means a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a specific therapeutic intervention, including known
gene-drug interactions for medications being considered for use or already
being administered. Biomarkers shall also include, but not be limited to, gene
mutations, characteristics of genes, or protein expression.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker testing includes but is not limited to,
single-analyte tests, multiplex panel tests, protein expression, and whole
exome, whole genome, and whole transcriptome sequencing.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Consensus statement means a statement developed by
an independent, multidisciplinary panel of experts utilizing a transparent methodology
and reporting structure and with a conflict of interest policy.  The statement
shall be aimed at specific clinical circumstances and be based on the best
available evidence for the purpose of optimizing the outcomes of clinical care.</span><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.</span><span style='font-size:11.5pt;line-height:150%;letter-spacing:
0pt'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      6.   a. 
Each individual health benefits plan that provides hospital or medical expense
benefits and is delivered, issued, executed, or renewed in this State pursuant
to P.L.1992, c.161 (C.17B:27A-2 et seq.) or is approved for issuance or renewal
in this State by the Commissioner of Banking and Insurance, on or after the
effective date of P.L. &nbsp;&nbsp;&nbsp;, c.    (C.        ) (pending before
the Legislature as this bill), shall provide benefits for biomarker testing, as
defined by subsection g. of this section.&nbsp;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      b.   Biomarker
testing shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition of a covered person
when the test is supported by medical and scientific evidence, including, but
not limited to:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1)  labeled
indications for an FDA-approved or -cleared test; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  indicated
tests for an FDA-approved drug; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (3)  warnings
and precautions on FDA-approved drug labels;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (4)  Centers
for Medicare and Medicaid Services National Coverage Determinations or Medicare
Administrative Contractor Local Coverage Determinations; or</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (5)  nationally-recognized
clinical practice guidelines and consensus statements.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      c.   Coverage,
pursuant to subsection b. of this section, shall be provided in a manner that
limits disruption, including multiple biopsies or biospecimen samples, in the
care of a covered person.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      d.   (1)        </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Notwithstanding any other law, rule, or regulation
to the contrary, if</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>If</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> utilization review is required, </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><u><span
style='letter-spacing:0pt'>a carrier shall provide</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> a decision </span><b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>shall be rendered on a prior authorization request,
and notice shall be sent to the covered person and the appropriate health care
provider, and if the request is made through a health care entity, to the
health care entity, within 72 hours for a non-urgent request or 24 hours for an
urgent request</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>pursuant
to the guidelines and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et
al.)</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>1</span></sup></b><span style='letter-spacing:0pt'>.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  The
covered person and the treating health care provider or treating health care
entity prescribing biomarker testing for the covered person shall have access
to clear, readily accessible, and conspicuous information on the process to
submit an appeal to an adverse determination.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      e.   The
benefits shall be provided to the same extent as for any other medical
condition under the health benefits plan.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      f.    The
provisions of this section shall apply to all health benefits plans in which
the carrier has reserved the right to change the premium.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      g.   As
used in this section:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
means a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a specific therapeutic intervention, including known
gene-drug interactions for medications being considered for use or already being
administered. Biomarkers shall also include, but not be limited to, gene
mutations, characteristics of genes, or protein expression.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker testing includes but is not limited to,
single-analyte tests, multiplex panel tests, protein expression, and whole
exome, whole genome, and whole transcriptome sequencing.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Consensus statement means a statement developed by
an independent, multidisciplinary panel of experts utilizing a transparent
methodology and reporting structure and with a conflict of interest policy. 
The statement shall be aimed at specific clinical circumstances and be based on
the best available evidence for the purpose of optimizing the outcomes of
clinical care.</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      7.   a.
&nbsp;Each small employer health benefits plan that provides hospital or
medical expense benefits and is delivered, issued, executed, or renewed in this
State pursuant to P.L.1992, c.162 (C.17B:27A-17 et seq.) or is approved for
issuance or renewal in this State by the Commissioner of Banking and Insurance,
on or after the effective date of P.L. &nbsp;&nbsp;&nbsp;, c.&nbsp; &nbsp;
(C.        ) (pending before the Legislature as this bill), shall provide
benefits for biomarker testing, as defined by subsection g. of this
section.&nbsp;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      b.   Biomarker
testing shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition of a covered person
when the test is supported by medical and scientific evidence, including, but
not limited to:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1)  labeled
indications for an FDA-approved or -cleared test; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  indicated
tests for an FDA-approved drug; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (3)  warnings
and precautions on FDA-approved drug labels;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (4)  Centers
for Medicare and Medicaid Services National Coverage Determinations or Medicare
Administrative Contractor Local Coverage Determinations; or</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (5)  nationally-recognized
clinical practice guidelines and consensus statements.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      c.   Coverage,
pursuant to subsection b. of this section, shall be provided in a manner that
limits disruption, including multiple biopsies or biospecimen samples, in the
care of a covered person.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      d.   (1)        </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Notwithstanding any other law, rule, or regulation
to the contrary, if</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>If</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> utilization review is required, </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><u><span
style='letter-spacing:0pt'>a carrier shall provide</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> a decision </span><b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>shall be rendered on a prior authorization request,
and notice shall be sent to the covered person and the appropriate health care
provider, and if the request is made through a health care entity, to the
health care entity, within 72 hours for a non-urgent request or 24 hours for an
urgent request</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>pursuant
to the guidelines and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et
al.)</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>1</span></sup></b><span style='letter-spacing:0pt'>.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  The
covered person and the treating health care provider or treating health care
entity prescribing biomarker testing for the covered person shall have access
to clear, readily accessible, and conspicuous information on the process to
submit an appeal to an adverse determination.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      e.   The
benefits shall be provided to the same extent as for any other medical
condition under the health benefits plan.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      f.    The
provisions of this section shall apply to all health benefits plans in which
the carrier has reserved the right to change the premium.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      g.   As
used in this section:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
means a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a specific therapeutic intervention, including known
gene-drug interactions for medications being considered for use or already
being administered. Biomarkers shall also include, but not be limited to, gene
mutations, characteristics of genes, or protein expression.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker testing includes but is not limited to,
single-analyte tests, multiplex panel tests, protein expression, and whole
exome, whole genome, and whole transcriptome sequencing.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Consensus statement means a statement developed by
an independent, multidisciplinary panel of experts utilizing a transparent
methodology and reporting structure and with a conflict of interest policy. 
The statement shall be aimed at specific clinical circumstances and be based on
the best available evidence for the purpose of optimizing the outcomes of
clinical care.</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.</span><span style='font-size:11.5pt;line-height:150%;letter-spacing:
0pt'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      8.     a.
&nbsp;Each health maintenance organization contract for health care services
that is delivered, issued, executed, or renewed in this State pursuant to
P.L.1973, c.337 (C.26:2J-1&nbsp;et&nbsp;seq.)&nbsp;or is approved for issuance
or renewal in this State by the Commissioner of Banking and Insurance, on or
after the effective date of P.L. &nbsp;&nbsp;&nbsp;, c. &nbsp;&nbsp; (C.       
) (pending before the Legislature as this bill), shall provide health care services
for biomarker testing, as defined by subsection g. of this section.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      b.   Biomarker
testing shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition of an enrollee when
the test is supported by medical and scientific evidence, including, but not
limited to:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1)  labeled
indications for an FDA-approved or -cleared test; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  indicated
tests for an FDA-approved drug; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (3)  warnings
and precautions on FDA-approved drug labels;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (4)  Centers
for Medicare and Medicaid Services National Coverage Determinations or Medicare
Administrative Contractor Local Coverage Determinations; or</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (5)  nationally-recognized
clinical practice guidelines and consensus statements.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      c.   Coverage,
pursuant to subsection b. of this section, shall be provided in a manner that
limits disruption, including multiple biopsies or biospecimen samples, in the
care of an enrollee.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      d.   (1)        </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Notwithstanding any other law, rule, or regulation
to the contrary, if</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>If</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> utilization review is required, </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><u><span
style='letter-spacing:0pt'>a health maintenance organization shall provide</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> a decision </span><b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>shall be rendered on a prior authorization request,
and notice shall be sent to the enrollee and the appropriate health care
provider, and if the request is made through a health care entity, to the
health care entity, within 72 hours for a non-urgent request or 24 hours for an
urgent request</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>pursuant
to the guidelines and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et
al.)</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>1</span></sup></b><span style='letter-spacing:0pt'>.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  The
enrollee and the treating health care provider or treating health care entity
prescribing biomarker testing for the enrollee shall have access to clear,
readily accessible, and conspicuous information on the process to submit an
appeal to an adverse determination.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      e.   The
health care services shall be provided to the same extent as for any other
medical condition under the contract.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      f.    The
provisions of this section shall apply to those contracts for health care
services by health maintenance organizations under which the right to change
the schedule of charges for enrollee coverage is reserved.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      g.   As
used in this section:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
means a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a specific therapeutic intervention, including known
gene-drug interactions for medications being considered for use or already
being administered. Biomarkers shall also include, but not be limited to, gene
mutations, characteristics of genes, or protein expression.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker testing includes but is not limited to,
single-analyte tests, multiplex panel tests, protein expression, and whole
exome, whole genome, and whole transcriptome sequencing.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Consensus statement means a statement developed by
an independent, multidisciplinary panel of experts utilizing a transparent
methodology and reporting structure and with a conflict of interest policy. 
The statement shall be aimed at specific clinical circumstances and be based on
the best available evidence for the purpose of optimizing the outcomes of
clinical care.</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      9.     a.
&nbsp;The State Health Benefits Commission shall ensure that every contract
providing hospital or medical expense benefits, which is purchased by the
commission on or after the effective date of P.L.&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill), provides coverage for biomarker
testing, as defined by subsection e. of this section.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      b.   Biomarker
testing shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition of a covered person
when the test is supported by medical and scientific evidence, including, but
not limited to:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1)  labeled
indications for an FDA-approved or -cleared test; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  indicated
tests for an FDA-approved drug; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (3)  warnings
and precautions on FDA-approved drug labels;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (4)  Centers
for Medicare and Medicaid Services National Coverage Determinations or Medicare
Administrative Contractor Local Coverage Determinations; or</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (5)  nationally-recognized
clinical practice guidelines and consensus statements.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      c.   Coverage,
pursuant to subsection b. of this section, shall be provided in a manner that
limits disruption, including multiple biopsies or biospecimen samples, in the
care of a covered person.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      d.   (1)        </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Notwithstanding any other law, rule, or regulation
to the contrary, if</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>If</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> utilization review is required, a decision shall be
rendered </span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>1</span></sup></b><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>[</span></b><span style='letter-spacing:0pt'>on a prior
authorization request, and notice shall be sent to the covered person and the
appropriate health care provider, and if the request is made through a health
care entity, to the health care entity, within 72 hours for a non-urgent
request or 24 hours for an urgent request</span><b><span style='font-family:
"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>]</span></b><span
style='letter-spacing:0pt'> <u>pursuant to the guidelines and timeframes set
forth in P.L.2023, c.296 (C.17B:30-55.1 et al.)</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'>.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  The
covered person and the treating health care provider or treating health care
entity prescribing biomarker testing to the covered person shall have access to
clear, readily accessible, and conspicuous information on the process to submit
an appeal to an adverse determination.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      e.   As
used in this section:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
means a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a specific therapeutic intervention, including known
gene-drug interactions for medications being considered for use or already
being administered. Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker testing includes but is not limited to,
single-analyte tests, multiplex panel tests, protein expression, and whole
exome, whole genome, and whole transcriptome sequencing.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Consensus statement means a statement developed by
an independent, multidisciplinary panel of experts utilizing a transparent
methodology and reporting structure and with a conflict of interest policy. 
The statement shall be aimed at specific clinical circumstances and be based on
the best available evidence for the purpose of optimizing the outcomes of
clinical care.</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      10. a.
&nbsp;The School Employees Health Benefits Commission shall ensure that every
contract providing hospital or medical expense benefits, which is purchased by
the commission on or after the effective date of P.L. &nbsp;&nbsp;&nbsp;, c.
&nbsp;&nbsp; (C.        ) (pending before the Legislature as this bill),
provides coverage for biomarker testing, as defined by subsection e. of this
section.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      b.   Biomarker
testing shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition of a covered person
when the test is supported by medical and scientific evidence, including, but
not limited to:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1)  labeled
indications for an FDA-approved or -cleared test; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  indicated
tests for an FDA-approved drug; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (3)  warnings
and precautions on FDA-approved drug labels;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (4)  Centers
for Medicare and Medicaid Services National Coverage Determinations or Medicare
Administrative Contractor Local Coverage Determinations; or</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (5)  nationally-recognized
clinical practice guidelines and consensus statements.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      c.   Coverage,
pursuant to subsection b. of this section, shall be provided in a manner that
limits disruption, including multiple biopsies or biospecimen samples, in the
care of a covered person.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      d.   (1)        </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Notwithstanding any other law, rule, or regulation
to the contrary, if</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>If</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> utilization review is required, a decision shall be
rendered </span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>1</span></sup></b><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>[</span></b><span style='letter-spacing:0pt'>on a prior
authorization request, and notice shall be sent to the covered person and the
appropriate health care provider, and if the request is made through a health
care entity, to the health care entity, within 72 hours for a non-urgent
request or 24 hours for an urgent request</span><b><span style='font-family:
"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>]</span></b><span
style='letter-spacing:0pt'> <u>pursuant to the guidelines and timeframes set
forth in P.L.2023, c.296 (C.17B:30-55.1 et al.)</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'>.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  The
covered person and the treating health care provider or treating health care
entity prescribing biomarker testing for the covered person shall have access
to clear, readily accessible, and conspicuous information on the process to
submit an appeal to an adverse determination.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      e.   As
used in this section:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
means a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a specific therapeutic intervention, including known
gene-drug interactions for medications being considered for use or already
being administered. Biomarkers shall also include, but not be limited to, gene
mutations, characteristics of genes, or protein expression.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker testing includes but is not limited to,
single-analyte tests, multiplex panel tests, protein expression, and whole
exome, whole genome, and whole transcriptome sequencing.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Consensus statement means a statement developed by
an independent, multidisciplinary panel of experts utilizing a transparent
methodology and reporting structure and with a conflict of interest policy. 
The statement shall be aimed at specific clinical circumstances and be based on
the best available evidence for the purpose of optimizing the outcomes of
clinical care.</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.</span><span style='font-size:11.5pt;line-height:150%;letter-spacing:
0pt'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      11. a. 
Notwithstanding any State law or regulation to the contrary, the Department of
Human Services shall ensure that expenses incurred for biomarker testing shall
be provided with no cost-sharing to persons served under the Medicaid program,
established pursuant to P.L.1968, c.413 (C.30:4D-1&nbsp;et&nbsp;seq.).</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      b.   Biomarker
testing shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition of an individual
when the test is supported by medical and scientific evidence, including, but
not limited to:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (1)  labeled
indications for an FDA-approved or -cleared test; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  indicated
tests for an FDA-approved drug; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (3)  warnings
and precautions on FDA-approved drug labels;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (4)  Centers
for Medicare and Medicaid Services National Coverage Determinations or Medicare
Administrative Contractor Local Coverage Determinations; or</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (5)  nationally-recognized
clinical practice guidelines and consensus statements.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      c.   Coverage,
pursuant to subsection b. of this section, shall be provided in a manner that
limits disruption, including multiple biopsies or biospecimen samples, in the
care of an individual.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      d.   If
the Division of Medical Assistance and Health Services in the Department of
Human Services contracts with a third-party entity to deliver biomarker testing
services pursuant to this section to beneficiaries under the Medicaid program,
the third-party entity shall provide biomarker testing at the same scope,
duration and frequency as the Medicaid program otherwise provides to
individuals.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      e.   (1)        </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>Notwithstanding any other law, rule, or regulation
to the contrary, if</span><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>]</span></b><span style='letter-spacing:0pt'> <u>If</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'> utilization review is required, a decision </span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>[</span></b><span
style='letter-spacing:0pt'>shall be rendered on a prior authorization request,
and notice be sent to an individual, the appropriate health care provider, and,
if necessary, the requisite health care entity if the request for prior
authorization was submitted through the entity, within 72 hours for a
non-urgent request or 24 hours for an urgent request</span><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>]</span></b><span
style='letter-spacing:0pt'> <u>shall be provided pursuant to the guidelines and
timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et al.)</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>1</span></sup></b><span
style='letter-spacing:0pt'>.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      (2)  The
individual and the treating health care provider or treating health care entity
prescribing biomarker testing for the individual shall have access to clear,
readily accessible, and conspicuous information on the process to submit an
appeal to an adverse determination.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      f.    As
used in this section:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
means a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a specific therapeutic intervention, including known
gene-drug interactions for medications being considered for use or already
being administered. Biomarkers shall also include, but not be limited to, gene
mutations, characteristics of genes, or protein expression.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>      Biomarker
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker testing includes but is not limited to,
single-analyte tests, multiplex panel tests, protein expression, and whole
exome, whole genome, and whole transcriptome sequencing.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:150%'>     12.  This act shall take
effect on the 90th day next following enactment and shall apply to policies and
contracts issued or renewed on or after the effective date. </p>

</div>

</body>

</html>
